Undervalued Paychex Exposure Increased

When I last reviewed Paychex (PAYX) in this March 27, 2025 post, the most current financial information was for Q3 and YTD2025. The March 26, 2025 closing share price was ~$150.20 and I thought a fair value was in the low-mid ~$130s. Fast forward to November 5, 2025. We now have PAYX's Q1 2026 results [...]

By |November 5th, 2025|Equity Investing|Comments Off on Undervalued Paychex Exposure Increased

ADP – Further Valuation Improvement Leads To Exposure Increase

On October 30, 2025, I disclose in my Exposure Increased As ADP Valuation Improves my decision to acquire an additional 200 shares @ $269.78 in a 'Core' account in the FFJ Portfolio on October 29. I conclude that post stating: I plan to acquire additional shares if ADP's valuation remains attractive. As luck would have [...]

By |November 3rd, 2025|Equity Investing|Comments Off on ADP – Further Valuation Improvement Leads To Exposure Increase

Improved Valuation Leads To An Increase In My Cintas Exposure

I recently covered Cintas (CTAS) in this my September 24, 2025 post. The reason for revisiting CTAS so soon is to disclose that on November 3, 2025 I acquired an additional 100 shares @ ~$181.455 in a 'Side' account in the FFJ Portfolio. My total exposure is now 700 shares. On October 28, CTAS released [...]

By |November 3rd, 2025|Equity Investing|Comments Off on Improved Valuation Leads To An Increase In My Cintas Exposure

Rollins Remains Richly Valued

I last reviewed Rollins (ROL) in this June 27, 2025 post in which I state: Rollins (ROL) may not appeal to some investors because the nature of its business is not 'sexy'. Sometimes, however, 'ho hum' businesses can offer investors the potential for very reasonable long-term total shareholder returns. Through its family of brands, ROL [...]

By |November 2nd, 2025|Equity Investing|Comments Off on Rollins Remains Richly Valued

FFJ Portfolio – October 2025

This FFJ Portfolio - October 2025 report is a high-level recap of my activity during the month. All monthly reports are accessible here. Recent Activity Purchases Automatic Data Processing (ADP) On October 29 I acquired 200 shares @ ~$269.78 in a 'Core' account in the FFJ Portfolio and disclose this purchase in my October 30 [...]

By |November 1st, 2025|FFJ Portfolio Holdings|Comments Off on FFJ Portfolio – October 2025

Intercontinental Exchange Grows Annual Recurring Revenue

When I last reviewed Intercontinental Exchange (ICE) in this August 3, 2024 post, I concluded that shares were no longer undervalued. At the time of that post, ICE had just released its Q2 and YTD2024 results on August 1, 2024. I now revisit this existing holding given the release of Q3 and YTD2025 results on [...]

By |October 31st, 2025|Equity Investing|Comments Off on Intercontinental Exchange Grows Annual Recurring Revenue

Thermo Fisher Remains Undervalued Despite Share Price Run-Up

I last reviewed Thermo Fisher (TMO) in this July 24, 2025 post. In that post I express disappointment in the share price surge. The share price had risen to ~$475 at the July 24 market close yet as recently as July 7, 2025, I purchased 75 shares @ $421.9667 share in a 'Core' account in [...]

By |October 31st, 2025|Equity Investing|Comments Off on Thermo Fisher Remains Undervalued Despite Share Price Run-Up

Exposure Increased As ADP Valuation Improves

In my March 27, 2024 Automatic Data Processing (ADP) guest post at Dividend Power I conclude shares are overvalued. I have been an ADP shareholder for decades. The majority of my exposure is through a tax efficient Registered Retirement Savings Plan (RRSP) account for which I do not disclose details. I have made no additional [...]

By |October 30th, 2025|Equity Investing|Comments Off on Exposure Increased As ADP Valuation Improves

CME Group – Capital Return Now Includes Share Repurchases

  In my July 26, 2025 CME Group Inc. (CME) post, I state that CME's Board authorized up to $3B in opportunistic share buybacks. On October 10, 2025, CME and S&P Global (SPGI) announced the completion of the sale of their 50/50 OSTTRA joint venture to KKR for ~$3.1B. Given these two events, I envision [...]

By |October 25th, 2025|Equity Investing|Comments Off on CME Group – Capital Return Now Includes Share Repurchases

Blackstone Exposure Increased

  At the time of my February 6, 2025 post, Blackstone (BX) had just released its Q4 and FY2024 results. The company's outlook for FY2025 suggested it would be a year of robust results. Looking at BX's Press Releases, we see that it has been extremely active. Recently, BX announced that funds managed by BX [...]

By |October 25th, 2025|Equity Investing|Comments Off on Blackstone Exposure Increased
Go to Top